Fate Therapeutics Inc (FATE)

[jondoeuk]

Another lentiviral vector https://www.businesswire.com/news/home/20251124182363/en/Kelonia-Therapeutics-Announces-Late-Breaking-Oral-Presentation-of-First-in-Human-Data-from-in-vivo-BCMA-CAR-T-Therapy-at-the-American-Society-of-Hematology-ASH-2025-Annual-Meeting

The abstract shows that all patients (N=3) experienced an MRD-negative response at month one. The patient with the longest follow-up to date maintained the MRD negativity at month three. All achieved a partial response at month one that deepened over time; the best response was a very good partial response (VGPR) at month three. All remain in response without disease progression.

Also, CAR-positive cells comprised 35%, 22%, and 72% of CD3+ lymphocytes on day fifteen showing expansion before. CAR-T cells were detected in the BM and peripheral blood through month three and were comprised predominantly of a memory-phenotype.